Our CEO Nicolas Wolikow explains why we start with the patients who survived and work backwards to understand the biology that made the difference.
Nicolas Wolikow, CEO, Cure51
Updated: September 30, 2026
Our CEO Nicolas Wolikow: "Our New Partnership with Servier Reflects Our Unique Approach to Glioblastoma Research"
Glioblastoma
The science
Publication Date:
Table of Contents
in THIS ARTICLE
In this article
NICOLAS WOLIKOW
Co-Founder CEO
MORE ARTICLES IN THIS TOPIC
RELATED ARTICLES
MORE TOP STORIES
Cure51 and Servier sign a long-term Target ID partnership on Glioblastoma in a deal up to €442M per target to discover novel therapies.
Building a Product Ecosystem for Cancer Target Discovery
CHUV Lausanne received their Rosalind trophy!
Our CEO Nicolas Wolikow: "Turning precision medicine into an operational reality"
How Cure51 Builds a Global Cancer Research Project Across 50+ Countries
